Data from in vivo research, however, allows us to highlight that PAI-1 antagonists might be an effective intervention to prevent the development of obesity and its sequelae by restoring leptin responsiveness with improved energy dissipation and thermogenic control. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.